Elevation of Peripheral BDNF Promoter Methylation Links to the Risk of Alzheimer’s Disease

Lan Chang1*, Yunliang Wang2,∗, Huihui Ji1, Dongjun Dai1,∗, Xuting Xu1, Danjie Jiang1, Qingxiao Hong1, Huadan Ye1, Xiaonan Zhang1, Xiaohui Zhou2, Yu Liu1, Jinfeng Li2, Zhongming Chen4, Ying Li5, Dongsheng Zhou4, Renjie Zhuo1, Yuzheng Zhang2, Honglei Yin3, Congcong Mao1, Shiwei Duan1,∗, Qinwen Wang1,∗

1 Zhejiang Provincial Key Laboratory of Pathophysiology, School of Medicine, Ningbo University, Ningbo, Zhejiang, China, 2 Department of Neurology, the 148 Central Hospital of PLA, Zibo, Shandong, China, 3 Department of Internal Medicine for Cadres, the First Affiliated Hospital of Xinjiang Medical University, Urumchi, China, 4 Ningbo Kangning Hospital, Zhejiang, China, 5 Ningbo No. 1 Hospital, Zhejiang, China

Abstract

Brain derived neurotrophic factor (BDNF) has been known to play an important role in various mental disorders or diseases such as Alzheimer’s disease (AD). The aim of our study was to assess whether BDNF promoter methylation in peripheral blood was able to predict the risk of AD. A total of 44 AD patients and 62 age- and gender-matched controls were recruited in the current case-control study. Using the bisulfite pyrosequencing technology, we evaluated four CpG sites in the promoter of the BDNF. Our results showed that BDNF methylation was significantly higher in AD cases than in the controls (CpG1: p = 10.021; CpG2: p = 0.002; CpG3: p = 0.007; CpG4: p = 0.005; average methylation: p = 0.004). In addition, BDNF promoter methylation was shown to be significantly correlated with the levels of alkaline phosphatase (ALP), glucose, Lp(a), ApoE and ApoA in males (ALP: r = −0.308, p = 0.042; glucose: r = −0.383, p = 0.010; Lp(a): r = 0.333, p = 0.027; ApoE: r = −0.345, p = 0.032), ApoA levels in females (r = 0.362, p = 0.033), and C Reactive Protein (CRP) levels in both genders (males: r = −0.373, p = 0.016; females: r = −0.399, p = 0.021). Our work suggested that peripheral BDNF promoter methylation might be a diagnostic marker of AD risk, although its underlying function remains to be elaborated in the future.

Introduction

Alzheimer’s disease (AD) is a neurodegenerative disorder characterized by progressive memory disorder and cognitive dysfunction [1]. The prevalence of AD was 26.6 million in 2006, and the number is expected to quadruple in 2050, causing a huge burden on both family and society [2]. AD is a complex disease affected by both environmental and genetic factors [3]. Twin studies showed that approximately 80% of cases resulted from inheritance [4]. Although a handful of genetic markers have been identified [5], the pathogenesis of AD remains unclear. Environmental factors were also shown to be related to AD [6].

As a link between genetic and environmental factors, epigenetic modification is able to cause stunted growth, mental retardation, feminization, and other complex syndromes [7,8]. Genes with aberrant DNA methylation could change gene expression levels [9], and thus, might contribute to the risk of diseases or disorders such as coronary heart disease [10,11], essential hypertension [12], schizophrenia [9], leukemia [13] and type 2 diabetes [7,14]. A global hypermethylation was found in the AD middle frontal gyrus and middle temporal gyrus with no apparent influence of gender, age, postmortem delay, or tissue storage time [15]. A decreased global DNA methylation level was also found in the hippocampus of AD patients [16].

The brain derived neurotrophic factor (BDNF) gene is located on chromosome 11p13, encoding a secretory protein of the neurotrophic factor family [17]. BDNF was shown to protect neurons from various attacks [18], and it was associated with several psychiatric disorders such as substance-related disorders, eating disorders, and schizophrenia [19]. Reduction in BDNF-immunoreactive cell bodies was found in AD patients [20]. A significantly higher BDNF promoter methylation level was found in the male schizophrenic patients [21] and in the depressive patients with suicidal behavior [22]. Prenatal stress was shown to induce decreased BDNF expression and increased methylation of the BDNF gene body in rats [23]. An increased level of BDNF promoter methylation and a decreased level of BDNF mRNA were simultaneously observed in the AD brain [24]. BDNF was
also treated as a new target in the AD treatment [25]. In this study, we measured BDNF promoter methylation levels in peripheral blood to explore its association with AD in the Han Chinese population.

**Methods and Materials**

A total of 44 sporadic AD cases and 62 matched controls were selected from Ningbo No. 1 Hospital and Ningbo Kangning Hospital. AD cases were diagnosed by experienced neurological physicians (CZ and ZQ) according to ICD-10 criteria, and confirmed by the evidence that comprised their medical and family histories, neurological examination, outcomes of blood tests, brain imaging examination (computed tomography or magnetic resonance), neuropsychological tests, as well as cognitive screening tests, including mini-mental state. No familial AD cases were included in the current study. At the time of sample collection, all the controls had been assessed to be free from any kind of disorder. All the individuals were Han Chinese originating from Ningbo city in Eastern China, and their characteristics are as described in Table 1. Blood samples were collected in 3.2% citrate sodium-treated tubes and then stored at $-80^\circ$C. The study protocol was approved by the Ethical Committees of Ningbo University, Ningbo No. 1 Hospital and Ningbo Kangning Hospital. Written informed consents were obtained from all the subjects through themselves or their guardians.

The content of serum total protein (TP) was measured by the biuret method [26], and serum albumin (ALB) was tested by the bromocresol green method [27]. Plasma levels of glutamic-pyruvic

| Characteristics | All subjects (n = 106) Mean ± SD. | Range (Overall) |
|-----------------|----------------------------------|-----------------|
| Age             | 79.78 ± 8.27                    | [53–96]         |
| Onset age       | 74.42 ± 11.35                   | [50–96]         |
| Course of disease | 7.02 ± 5.30                    | [0–20]          |
| Hypertension (Yes/No) | 71/35                      | /              |
| Smoking (Yes/No)         | 17/89                           | /              |
| Diabetes (Yes/No)         | 32/74                           | /              |
| Drugs (Memantine/Exelon/Aricept) | 17/3/15                  | /              |
| CpG1 (%)        | 10.69 ± 4.26                    | [5–38]          |
| CpG2 (%)        | 5.22 ± 3.25                     | [1–29]          |
| CpG3 (%)        | 8.43 ± 3.91                     | [2–25]          |
| CpG4 (%)        | 8.87 ± 4.06                     | [0–26]          |
| Mean BDNF methylation (%) | 8.30 ± 3.68                 | [2.5–29.5]      |

doi:10.1371/journal.pone.0110773.t001

**Figure 1. Correlation among 4 CpGs in BDNF promoter.** F: Forward primer, R: Reverse primer, S: Sequencing primer.
doi:10.1371/journal.pone.0110773.g001
transaminase (ALT), alkaline phosphatase (ALP) and glutamic oxalacetic transaminase (AST) were determined by the velocity method [28,29]. The levels of total bile acid (TBA) and homocysteine (Hcy) were measured by the cycling enzymatic method [30,31]. The concentrations of blood glucose (Glu), triglyceride (TG), total cholesterol (TC), carbamide (UREA), creatinine (CRE) and uric acid (UA) in plasma were determined using the classic enzymatic methods [32–37]. The high-density lipoprotein cholesterol (HDL-C) level was determined by the one-step detection method [38]. The proportion of apolipoprotein A (ApoA) and apolipoprotein B (ApoB) were measured by turbidimetry [39,40]. The content of lipoprotein A (Lp(a)) was detected using the endpoint method [41]. C Reactive Protein (CRP) and apolipoprotein E (ApoE) were measured by using a latex agglutination assay [42] and an immunoturbidimetric assay [43], respectively.

Human genomic DNA was extracted from peripheral blood samples using the nucleic acid extraction analyzer (Lab-Aid 820, Xiamen City, China). DNA concentrations were determined by using the ultramicro nucleic acid ultraviolet tester (NanoDrop 2000, Wilmington, USA). DNA methylation was measured by using pyrosequencing technology, which combines sodium bisulfite DNA conversion chemistry (EZ DNA Methylation-GoldTM Kit; ZYMO RESEARCH), polymerase chain reaction (PCR) amplification (Zymo TaqTM PreMix, ZYMO RESEARCH) and sequencing by synthesis assay (Pyromark Gold Q24 Reagents; Qiagen) of the CGI region on BDNF promoter. PCR primers were designed by PyroMark Assay Design software. Sequences of the PCR primers were shown in Table S1.

All of the statistical analyses were performed by Statistical Program for Social Sciences (SPSS) software 16.0 (SPSS, Inc., Chicago, IL, USA) and a p value <0.05 was considered to be significant. Two independent samples t-test was used to compared differences in the mean values of continuous variables between the AD cases and controls. The associations between BDNF methylation and metabolic characteristics of AD subjects were assessed by Pearson’s correlation test. Bonferroni correction was used to adjust our results.

**Results**

As shown in Figure 1, a total of four CpGs on a fragment in the BDNF promoter were included in this specific methylation assay. Methylation levels of the four CpGs were significantly correlated with each other (Figure 1, r=0.8, p=0.001). Therefore, associa-

**Table 2. Comparisons of BDNF methylation levels between cases and controls.**

| Characteristics | Case Mean ± SD | Control Mean ± SD | p value |
|-----------------|----------------|------------------|---------|
| All             |                |                  |         |
| CpG1 (%)        | 11.82±5.32     | 9.89±3.13        | 0.021   |
| CpG2 (%)        | 6.39±4.27      | 4.39±1.92        | 0.002#  |
| CpG3 (%)        | 9.64±4.24      | 7.58±3.45        | 0.007   |
| CpG4 (%)        | 10.16±4.69     | 7.95±3.29        | 0.005   |
| Mean BDNF methylation (%) | 9.50±4.43    | 7.45±2.77        | 0.004#  |
| Male            |                |                  |         |
| CpG1 (%)        | 10.85±2.87     | 9.87±2.72        | 0.191   |
| CpG2 (%)        | 5.60±1.98      | 4.42±1.73        | 0.018   |
| CpG3 (%)        | 8.25±2.53      | 7.40±2.79        | 0.249   |
| CpG4 (%)        | 8.80±2.91      | 7.96±3.07        | 0.303   |
| Mean BDNF methylation (%) | 8.38±2.46    | 7.41±2.39        | 0.142   |
| Female          |                |                  |         |
| CpG1 (%)        | 12.62±6.67     | 9.94±4.12        | 0.150   |
| CpG2 (%)        | 7.04±5.47      | 4.29±2.42        | 0.060   |
| CpG3 (%)        | 10.79±5.02     | 8.06±4.85        | 0.090   |
| CpG4 (%)        | 11.29±5.58     | 7.94±3.90        | 0.039   |
| Mean BDNF methylation (%) | 10.44±5.45   | 7.56±3.67        | 0.066   |

* p value less than or equal to 0.05 is in bold.
# p value survived after multiple testing.
doi:10.1371/journal.pone.0110773.t002

As shown in Figure 2, a total of four CpGs on a fragment in the BDNF promoter were included in this specific methylation assay. Methylation levels of the four CpGs were significantly correlated with each other (Figure 1, r>0.8, p<0.001). Therefore, associa-
Association between BDNF Promoter Methylation and AD

Table 3. Characteristics of subjects from cases and controls.

| Characteristics        | Case (n = 44) | Control (n = 62) | p value |
|------------------------|--------------|-----------------|--------|
| Age (years)            | 80.00±6.92   | 79.63±7.85      | 0.821  |
| TP (g/L)               | 68.74±6.80   | 65.77±9.58      | 0.135  |
| ALB (g/L)              | 38.43±3.82   | 36.65±3.89      | 0.045  |
| GLB (g/L)              | 30.31±5.30   | 30.03±5.70      | 0.830  |
| A/G                    | 1.31±0.22    | 1.27±0.23       | 0.432  |
| ALT (U/L)              | 13.81±10.51  | 18.12±13.34     | 0.183* |
| ALP (U/L)              | 78.96±24.27  | 96.33±62.80     | 0.147* |
| BTA (µmol/L)           | 6.80±3.81    | 5.96±5.85       | 0.499  |
| Glu (mmol/L)           | 5.18±1.57    | 5.51±2.69       | 0.359b |
| TG (mmol/L)            | 1.34±0.77    | 1.41±0.97       | 0.896a |
| TC (mmol/L)            | 4.43±1.04    | 4.25±1.24       | 0.430  |
| HDL-C (mmol/L)         | 1.06±0.20    | 1.03±0.30       | 0.136  |
| ApoA (g/L)             | 1.06±0.21    | 0.93±0.20       | 0.006  |
| ApoB (g/L)             | 0.66±0.18    | 0.72±0.26       | 0.235  |
| Lp(a) (g/L)            | 179.19±231.22| 34.56±27.13     | 1.68E-04*|
| ApoE (mg/L)            | 37.73±17.44  | 36.69±10.37     | 0.800  |
| UREA (mmol/L)          | 7.72±9.84    | 6.45±3.42       | 0.776b |
| CRE (µmol/L)           | 82.09±46.59  | 78.83±29.82     | 0.700  |
| UA (µmol/L)            | 308.39±104.87| 308.41±111.66   | 0.999  |
| Hcy (µmol/L)           | 19.76±10.82  | 17.64±20.63     | 0.045* |
| CRP (mg/L)             | 6.20±11.72   | 14.84±25.97     | 0.014* |
| Mean BDNF methylation (%) | 9.50±4.43  | 7.45±2.77       | 0.004  |

*p value less than or equal to 0.05 is in bold. a: Log-transformation was used. b: Nonparametric rank test was applied. TP: total protein; ALB: serum albumin; GLB: serum globulin; A/G: ALB/GLB; ALT: glutamic-pyruvic transaminase; ALP: alkaline phosphatase; TBA: total bile acid; AST: glutamic oxalacetic transaminase; Glu: blood glucose; Hcy: homocysteine; CRP: C Reactive Protein.

doi:10.1371/journal.pone.0110773.t003

As shown in Table 2 and Figure 2, BDNF promoter methylation was significantly elevated in the AD cases as opposed to the controls (CpG1: p = 0.021; CpG2: p = 0.002; CpG3: p = 0.007; CpG4: p = 0.003; average methylation: p = 0.004). A further subgroup analysis by gender showed significant associations with AD for CpG2 methylation in males (p = 0.018, Table 2) and CpG4 methylation in females (p = 0.039, Table 2). The lack of association for the other tests might be due to a lack of power in the subgroup analyses by gender. In addition, our results showed that there was no significant interaction between AD drugs and BDNF methylation or individual CpG sites (p > 0.05, Figure S1 and Table S2).

A total of 22 phenotypes were collected for all of the involved samples (Table 3). Significantly higher levels of ALB (p = 0.045), ApoA (p = 0.006), Lp(a) (p = 1.68E-04) and Hcy (p = 0.045) were found in the AD cases. A significantly lower CRP level (p = 0.014) was also found in the AD cases. As shown in Figure 3, further subgroup tests by gender showed that male-specific associations were only found between BDNF promoter methylation and ALP (r = −0.308; p = 0.042), glucose (r = −0.383; p = 0.010), Lp(a) (r = 0.333; p = 0.027), and ApoE (r = −0.345; p = 0.032). Significant association between BDNF promoter methylation and ApoA was only found in females (r = 0.362; p = 0.033). Otherwise, we observed CRP was significantly associated with BDNF promoter methylation in both genders (males: r = −0.373, p = 0.016; females: r = −0.399, p = 0.021).

Age is an important factor for AD, however, our correlation tests showed a lack of association between BDNF methylation and age (Table S3). A breakdown analysis by gender also found no association of age with all CpGs in both gender subgroups. Also, no association was found between BDNF methylation and the onset of increased age in the all samples and subgrouped samples by gender (Table S4).

Discussion

About 40% of promoters in mammalian genes were hypermethylated [44] and promoter hypermethylation often silences gene expression [45]. Aberrant promoter methylation exists in several diseases such as essential hypertension [12], type 2 diabetes [14], schizophrenia [9], coronary heart disease [9,10], leukemia [13], and colorectal cancer [46]. Higher DUSP22 promoter methylation was found in AD brain tissues [47]. Lower SORL1 promoter methylation was found in the brain and blood of AD patients [48]. Our study showed there was a significantly elevated methylation of the BDNF promoter in peripheral blood. Our findings agreed to the previous observation that higher BDNF promoter methylation was found in the brain tissues of AD.
patients [24] and gave a new hint for the diagnosis of AD using the peripheral blood as a surrogate.

Decreased BDNF promoter methylation levels were shown to be correlated with increased BDNF mRNA and protein expression in the epileptic hippocampus [49]. Reductions of BDNF protein in frozen postmortem AD frontal cortex samples compared to controls showed reduced mRNA levels of BDNF, which might be related to the hypermethylated BDNF promoter in the same tissues [24]. Decreased BDNF expression in the amygdala and hippocampus of prenatally stressed rats, both at weaning and in adulthood, was found to be accompanied by increased BDNF gene body methylation [23]. The elevation of BDNF promoter methylation in AD peripheral blood might indicate a decreased BDNF expression, although future work is needed to confirm our speculation.

Gender disparities are widely shown in AD. Women are shown to be at a higher risk for AD in all the age stratums and the age-adjusted odds ratio for women was 3.1 between AD cases and controls [50]. Meta-analyses of 16 human case-control studies observed significant associations between BDNF Val66Met and AD in females, but not in males [51]. Animal testing with aged mice found a higher level of the BDNF gene in female mice, but not in male mice, and female mice were more sensitive to kainic acid-induced excitotoxicity, which can lead to hippocampal neurodegeneration [52]. Previous studies also indicated that gender-specific DNA methylation existed in mice [53] and humans [10,54]. In this study, we observed that methylation of all four CpGs were significantly elevated in AD patients than in controls. In the subgroup analyses by gender, our results showed that BDNF CpG2 and CpG4 methylation was significantly higher.
in male and female AD cases, respectively, and that a trend towards a significant result was found in females for average methylation and CpG2. Our work suggests that BDNF promoter methylation might have gender dimorphism in the association of BDNF methylation with AD. Further studies with larger samples need to be done to confirm our observation.

A total of 22 phenotypes were analyzed among our subjects. A significant association of AD was found for ApoA, which plays a role in cholesterol transport and the regulation of inflammation [55] as well as affects Aβ aggregation and deposition [56]. A previous study showed that serum ApoA concentration was highly correlated with the severity of AD [57]. A significant association of AD was found with Lp(a), which was shown to be related to dementia [58] and AD [59]. A significant association of AD with ALB was found in our study. Human serum ALB could indicate AD by regulating Aβ peptide fiber growth in the brain interstitium [60]. A significantly higher level of Hcy was also found in this present study. A higher level of Hcy was a risk factor of AD [61] and may cause learning and memory deficits by generating reactive oxygen species [62]. CRP involved in the systemic response to inflammation [63], and our results were consistent with an earlier study which found reduced levels of plasma CRP in AD [64].

Gender-stratified correlation analyses were also performed between BDNF promoter methylation and the 22 phenotypes. Among them, we observed four significant associations in males, a significant association of ApoA in females, and a significant association of CRP in both genders. Our results suggest that BDNF promoter methylation might influence the pathophysiology of AD through its influence on those factors. This might also provide new hints to elucidate the molecular mechanisms in AD pathogenesis.

There are several limitations of our study that need to be taken into consideration. Firstly, there were only 44 cases and 62 controls in our study. The moderate number of samples may have influenced the results of our study, especially for the gender-stratified association test of BDNF methylation with AD. Secondly, although the best-scored primers harbor a fragment with 4 CpGs which might not fully represent the overall contribution of BDNF methylation to AD patients. Further studies of other CpGs in the promoter and gene body are needed. Thirdly, since we could not obtain the brain tissues, we only tested the DNA methylation levels of BDNF in peripheral blood. Further comprehensive studies are needed to test the concordance of BDNF methylation between brain tissues and peripheral blood. Fourthly, aged persons have a tendency to get different illnesses. Although we tried our best to avoid potential factors when we matched the cases and controls, unknown factors exist in the samples that might influence the results of our work. Fifthly, we assessed four CpG positions per pyrosequencing, so some p values might not retain their significance after being corrected by the number of CpG sites. A chance of random positive findings could not be excluded. We marked the p values that remained significant after multiple test corrections. We kept the uncorrected p values in the tables and annotated some with the correction methods for the readers’ reference.

Conclusions

Our study suggested that there was a significant contribution of BDNF promoter methylation to the risk of AD. Aberrant BDNF methylation in peripheral blood could serve as a surrogate for the diagnosis of AD. In addition, our study also found that BDNF methylation was associated with several biomedical factors, which consisted of ALP, Glucose, Lp(a) and ApoE in males, ApoA in females and CRP in both genders.

Supporting Information

Figure S1 Comparison of BDNF promoter methylation among AD patients with different drug treatment. (TIF)
Table S1 Primers for BDNF methylation analysis. (DOC)
Table S2 Correlation analyses between BDNF promoter methylation levels and AD drugs. (DOC)
Table S3 Correlation analyses between BDNF promoter methylation levels and onset age in total, males and females samples. (DOC)
Table S4 Correlation analyses between BDNF promoter methylation levels and onset age in total, males and females samples. (DOC)

Author Contributions

Conceived and designed the experiments: SD QW YW. Performed the experiments: LC HJ XX QH H. Ye Y. Liu YZ H. Yin X. Zhang. Analyzed the data: HJ DJ RZ. Contributed reagents/materials/analysis tools: HJ CM JL ZC Y. Li X. Zhou DZ. Wrote the paper: HJ DD DJ.

References

1. Mucke L (2009) Neuroscience: Alzheimer’s disease. Nature 461: 895–897.
2. Brookmeyer R, Johnson E, Ziegler-Graham K, Arrighi HM (2007) Forecasting the global burden of Alzheimer’s disease: the Journal of the Alzheimer’s Association 3: 139–191.
3. Kubota T (2013) Epigenome: what we learned from Rett syndrome, a neurological disease caused by mutation of a methyl-CpG binding protein). Rinsho shinkeigaku = Clinical neurology 53: 1339–1341.
4. Rao AT, Degnan AJ, Levy LM (2014) Genetics of Alzheimer disease. AJNR American journal of neuroradiology 35: 457–458.
5. Xu X, Wang Y, Wang L, Liao Q, Chang L, et al. (2013) Meta-analyses of 8 polymorphisms associated with the risk of the Alzheimer’s disease. PloS one 8: e73129.
6. Copepepe F, Ziturzo MT, Migelli F, Lo Gerfo A, Bagnoli S, et al. (2012) DNMT3B promoter polymorphisms and risk of late onset Alzheimer’s disease. Current Alzheimer research 9: 550–554.
7. Tang LL, Liu Q, Bu SZ, Xu LT, Wang QW, et al. (2013) [The effect of environmental factors and DNA methylation on type 2 diabetes mellitus]. Yi chuan = Hereditas/Zhongguo yi chuan xue hui bian jii 35: 1143–1152.
8. Maloney B, Sambamurti K, Zawia N, Lahiri DK (2012) Applying epigenetics to Alzheimer’s disease via the latent early-life associated regulation (LEARn) model. Current Alzheimer research 9: 589–599.
9. Cheng J, Yang X, Wang K, Wang L, Li J, et al. (2014) Male-specific association between dopamine receptor D4 gene methylation and schizophrenia. PloS one 9: e89128.
10. Jiang D, Zheng D, Wang L, Huang Y, Liu H, et al. (2013) Elevated PLA2G7 gene promoter methylation as a gender-specific marker of aging increases the risk of coronary heart disease in females. PloS one 8: e59752.
11. Xu L, Zheng D, Wang L, Jiang D, Liu H, et al. (2014) GCK Gene-Body Hypomethylation Is Associated with the Risk of Coronary Heart Disease. BioMed research international 2014: 131723.
12. Zhang L, Liu PP, Wang L, Yuan F, Xu L, et al. (2013) Lower ABD1 gene promoter DNA methylation increases the risk of essential hypertension. PloS one 8: e63545.
13. Jiang D, Hong Q, Shen Y, Xu Y, Zhu H, et al. (2014) The diagnostic value of DNA methylation in leukemia: a systematic review and meta-analysis. PloS one 9: e96822.
Association between BDNF Promoter Methylation and AD

14. Cheng, J, Wang L, Xu L, Wang H, Liu P, et al. (2013) Gender-dependent miR-375 promoter methylation and the risk of type 2 diabetes. Experimental and therapeutic medicine 5: 1607–1609.

15. Coppoleros N, Dierks BV, Litt C, Faull RL, Curris MA, et al. (2014) Global chromatin and DNA methylation and hydroxymethylation in the hippocampus of Alzheimer’s disease patients. Neurobiology of aging 35: 1334–1344.

16. Choudhuri L, Mastroeni D, Delvalle A, Grover A, Kenis G, et al. (2013) Consistent decrease in global DNA methylation and hydroxymethylation in the hippocampus of Alzheimer’s disease patients. Neurobiology of aging 34: 2091–2099.

17. Maisonneuve PC, Le Beau MM, Epipso-S 3rd, Ip NY, Bellocco L, et al. (1991) Human and rat brain-derived neurotrophic factor and neurotrophin-3: gene structures, distributions, and chromosomal localizations. Genomics 10: 538–561.

18. Yang JL, Liu YT, Chuang PC, Bohr VA, Mattson MP (2014) BDNF and exercise enhance neuronal DNA repair by stimulating CREB-mediated production of apurinic/apyrimidinic endonuclease-1. Neuro molecular medicine 16: 161–174.

19. Gratacos M, Gonzalez JR, Mercader JM, de Cid R, Urretavizcaya M, et al. (2007) Brain-derived neurotrophic factor Val66Met and psychiatric disorders: meta-analysis of case-controlled studies confirm association to substance-related disorders, eating disorders, and schizophrenia. Biological psychiatry 61: 911–922.

20. Cornish B, Young D, Yan Q, Faull RL, Synek B, et al. (1997) Brain-derived neurotrophic factor is reduced in Alzheimer’s disease. Brain research. Molecular brain research 49: 71–81.

21. Ikage T, Bundo M, Sumaga F, Asai T, Nishimura F, et al. (2013) DNA methylation status of BDNF gene promoters in peripheral blood cells of schizophrenia patients. Neuroscience research 77: 208–214.

22. Kang HJ, Kim JM, Lee JY, Kim SY, Bae KY, et al. (2013) BDNF promoter methylation and suicidal behavior in depressive patients. Journal of affective disorders 155: 679–683.

23. Boersma GJ, Lee RS, Cordero ZA, Ewald ER, Purcell RH, et al. (2013) Prenatal stress decreases expression and increases methylation of exon IV in rats. Epigenetics: official journal of the DNA Methylation Society 9.

24. Rao JS, Keishin VL, Klein S, Rapoport SI (2012) Epigenetic modifications in frontal cortex from Alzheimer’s disease and bipolar disorder patients. Translational psychiatry 2: e132.

25. Russo-Neustadt A (2005) Brain-derived neurotrophic factor behavior, and new directions for the treatment of mental disorders. Seminars in clinical neuropsychiatry 8: 109–118.

26. Doumas BT (1975) Standards for total serum protein assays—a collaborative study. Clinical chemistry 21: 1139–1166.

27. McPherson RJ, Everard DW (1972) Serum albumin estimation: modification of the bromocresol green method. Clinica chimica acta; international journal of clinical chemistry 37: 117–121.

28. Nath RL, Ghosh NK (1962) A preliminary report on the determination of the normal values of serum alkaline phosphatase activity by velocity constant method. Bulletin of the Calcutta School of Tropical Medicine 10: 71–72.

29. Yang X, Liu B, Sang Y, Yuan Y, Pu J, et al. (2010) Kinetic analysis of the lactate-dehydrogenase-coupled reaction process and measurement of alanine transaminase by using polypeptide AI and AP as an indicator. Analytical sciences: the international journal of the Japan Society for Analytical Chemistry. 26: 1193–1198.

30. Roberts RF, Roberts WL (2004) Performance characteristics of a recombinant enzymatic cycling assay for quantification of total homocysteine in serum or plasma. Clinica chimica acta; international journal of clinical chemistry 344: 95–101.

31. Zhang GH, Cong AR, Xu GB, Li CB, Yang RF, et al. (2003) An enzymatic cycling method for the determination of serum total bile acids with recombinant 3alpha-hydroxysteroid dehydrogenase. Biochemical and biophysical research communications 326: 87–92.

32. Astrow G (1969) Semiautomated enzymic micro methods for blood glucose and lactic acid on a single filter. Analytical biochemistry 20: 130–135.

33. Hinziker P, Keller H (1973) [A mechanized enzymic method for the determination of uric acid (author’s transl)]. Zeitschrift fur klinische Chemie und klinische Biologie 13: 89–96.

34. Jaynes PK, Feld RD, Johnson GF (1982) An enzymic, reaction-rate assay for serum creatinine with a centrifugal analyzer. Clinical chemistry 28: 114–117.

35. Knob M, Rosenmund H (1975) [Enzymic determination of total serum cholesterol]. Annales de biologie clinique 57: 561–572.

36. DaCoP, Kostner GM (1983) Immunoquantification of total apolipoprotein B in serum by nephelometry: influence of lipase treatment and detergents. Clinical chemistry 29: 1045–1056.

37. Girault A, Loiseau D, Girault M (1981) [Quantitative determination of apolipoprotein A in human serum by laser nephelometry]. La Ricerca in clinica e in laboratorio 11 Suppl 2: 19–29.

38. Cazzolato G, Prakash G, Green S and Kostner GM (1983) The determination of lipoprotein Lp(a) by rate nephelometry. Clinica chimica acta; international journal of clinical chemistry 135: 203–204.

39. Deyo RA, Pope RM, Persellin RH (1989) Interference by rheumatoid factor with the detection of C-reactive protein by the latex agglutination method. The Journal of clinical pathology 7: 279–287.

40. Rizzi N, Silverman LM (1987) A simple immunotechnique for the determination of serum concentration of apolipoprotein E. Clinica chimica acta; international journal of clinical chemistry 163: 207–213.

41. Fauci A, Masuoka F, Higuchi H, Maeda K, Egger G, et al. (2005) Footprinting of mammalian promoters: use of a Cpg DNA methyltransferase releasing nucleoside positions at a single molecule level. Nucleic acids research 33: e176.

42. Deaton AM, Bird A (2011) CpG islands and the regulation of transcription. Nature & development 25: 101–109.

43. Chen C, Wang L, Liao Q, Huang Y, Ye H, et al. (2013) Hypermethylation of EDRNRB promoter contributes to the risk of colorectal cancer. Diagnostic pathology 19: 199.

44. PremN, Patel V, Aoo E, Heya H, Matsuda T, Bock C, et al. (2014) Promoter hypermethylation of the phosphatase DUSP22 mediates PKA-dependent TAU phosphorylation and CREB activation in Alzheimer’s disease. Hippocampus 24: 363–366.

45. Furuya TK, da Silva PN, Payson SL, Rasmussen LT, de Lafont R, et al. (2012) SORL1 and SIRT1 mRNA expression and promoter methylation levels in aging and Alzheimer’s Disease. Neurochemistry international 61: 973–975.

46. Ryley Parrish R, Albertson AJ, Buckingham SC, Hablitz JJ, Mascia KL, et al. (2013) Status epilepticus triggers early and late alterations in brain-derived neurotrophic factor and NPY receptor gene expression in the mouse brain. Brain research 1521: 132–138.

47. Fukunoto N, Fujii T, Combarros O, Kamboh MI, Tsai SJ, et al. (2010) Sexually dimorphic effect of the Val66Met polymorphism of BDNF on susceptibility to Alzheimer’s disease: new data and meta-analysis. American journal of medical genetics Part B, Neuropsychiatric genetics: the official publication of the International Society of Psychiatric Genetics 153B: 235–242.

48. Zhang XM, Zhu SW, Duan RS, Mohammed AH, Winblad B, et al. (2008) Gender differences in susceptibility to kainic acid-induced neurodegeneration in aged C57BL/6 mice. Neuroreport 19: 406–412.

49. Penalova CG, Estevez B, Han DM, Norouzi M, Lockshin RA, et al. (2014) Sex-dependent regulation of cytochrome P450 family members Cyp1a1, Cyp2e1, and Cyp2h1 by methylation of DNA. FASEB journal: official publication of the Federation of American Societies for Experimental Biology 28: 966–977.

50. Pifferer F (2013) Epigenetics of sex determination and gonadogenesis. Developmental dynamics: an official publication of the American Association of Anatomists 242: 360–370.

51. Kresey JE, Swoomley AM, Forster S, Harris JL, Sultana R, et al. (2013) Apolipoprotein A-IV: insights from redox proteomics for its role in neurodegeneration. Proteomics Clinical applications 7: 109–122.

52. Kawasaki M, Kawakami M, Otsuka M, Yashima H, Yaginuma T, et al. (1995) Marked decrease of plasma apolipoprotein AI and ApoB and ApoAI: ApoB ratio in Japanese patients with late-onset non-familial Alzheimer’s Disease. Clinica chimica acta; international journal of clinical chemistry 239: 209–211.

53. Fagan AM, Younkin LH, Morris JC, Fryer JD, Cole TG, et al. (2000) Status epilepticus triggers early and late alterations in brain-derived neurotrophic factor and NMDA glutamate receptor and Grin1 gene DNA methylation levels in the hippocampus. Neuroscience 240C: 602–619.

54. Fagan AM, Younkin LH, Morris JC, Fryer JD, Cole TG, et al. (2000) Status epilepticus triggers early and late alterations in brain-derived neurotrophic factor and NMDA glutamate receptor and Grin1 gene DNA methylation levels in the hippocampus. Neuroscience 240C: 602–619.

55. Yarchoan M, Louneva N, Xie SX, Swenson FJ, Hu W, et al. (2013) Association between BDNF Promoter Methylation and AD...